p53 Variant Liquid-Liquid Phase Separation for Tumor Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current p53 gene therapies for cancer treatment face limitations due to instability of wild-type p53 and gain-of-function effects by mutant p53, leading to reduced therapeutic efficacy, necessitating the development of p53 variants with enhanced tumor inhibition capabilities.
Innovation Solution
Designing p53 variants with improved liquid-liquid phase separation ability by incorporating an amino acid sequence rich in positive charges and histidine at one terminus, along with a linker sequence, which enhances transactivation activity and tumor suppression capabilities, and combining these variants with small-molecule inhibitors for improved anti-tumor effectiveness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If wild-type p53 is used for gene therapy, then the therapy can be clinically approved and deliver p53 to tumor cells, but the instability of wild-type p53 and gain-of-function effects by mutant p53 reduce therapeutic efficacy
Solution Approach 1:
The patent modifies the p53 protein by changing its amino acid sequence parameters - specifically adding a C-terminal tail with enriched positively charged amino acids (arginine and lysine) and histidine residues. This parameter change transforms the unstable wild-type p53 into a more stable variant with enhanced liquid-liquid phase separation ability, directly resolving the contradiction between stability and therapeutic efficacy
Solution Approach 2:
The patent creates a composite structure by combining the core p53 protein domain with an additional C-terminal tail segment. This composite design integrates the tumor suppressor function of p53 with the phase separation-enhancing properties of the positively charged tail, resulting in a hybrid protein that overcomes the limitations of wild-type p53 while maintaining its therapeutic function
2Productivity
If p53 variants with enhanced phase separation ability are designed, then transactivation activity and tumor suppression are improved, but the protein structure becomes more complex
Solution Approach 1:
The patent segments the p53 protein into functional domains: the core p53 transcription factor domain and an added C-terminal tail segment. This segmentation allows the core domain to maintain its established function while the separate tail segment provides enhanced phase separation ability, improving transactivation activity without disrupting the core structure
Solution Approach 2:
The patent applies partial action by adding only the specific C-terminal tail segment with positively charged amino acids rather than redesigning the entire p53 protein. This targeted modification provides sufficient enhancement in phase separation and transactivation activity while minimizing structural complexity increases
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The p53 variants demonstrate stronger liquid-liquid phase separation and transactivation activity, significantly suppressing tumor cell growth and enhancing anti-tumor effects when combined with FGFR or Wnt signaling pathway inhibitors, offering a promising clinical approach for cancer treatment.
Implementation Method 1
p53 variants with improved liquid-liquid phase separation ability
Data Source
AI summary
This disclosure provides a p53 variant with improved liquid-liquid phase separation ability and activity and use thereof. Compared with wild-type p53, the novel p53 variant has following advantages: 1) stronger liquid-liquid phase separation ability; 2) stronger transcriptional activation ability for p53 target genes such as CDKN1A, in tumor cells; 3) more remarkable growth inhibition effect on various tumor cells. This disclosure demonstrates that improving the liquid-liquid phase separation ability can enhance transcriptional activation activity of p53 and induce growth inhibition of tumor cells, which is of great significance for improving p53-based gene/protein therapy. Gene and protein of the p53 variant disclosed by this invention are promising anti-cancer agents with potential for clinical use. Additionally, when combined with the FGFR inhibitor TAS-120 or the Wnt pathway inhibitor IWR-1, the p53 variant shows enhanced tumor-suppressive efficacy.